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Abstract
AIM
To identify whether CpG island methylator phenotype 
(CIMP) is predictive of response to neoadjuvant chemor-
adiotherapy (NACRT) and outcomes in rectal cancer.
METHODS
Patients undergoing NACRT and surgical resection 
for rectal cancer in a tertiary referral centre between 
2002-2011 were identified. Pre-treatment tumour biopsies 
were analysed for CIMP status (high, intermediate or low) 
using methylation specific PCR. KRAS and BRAF status 
were also determined using pyrosequencing analysis. 
Clinical information was extracted from case records and 
cancer services databases. Response to radiotherapy was 
measured by tumour regression scores determined upon 
Submit a Manuscript: http://www.f6publishing.com/helpdesk
DOI: 10.4251/wjgo.v9.i5.209
World J Gastrointest Oncol  2017 May 15; 9(5): 209-217
ISSN 1948-5204 (online)
210 May 15, 2017|Volume 9|Issue 5|WJGO|www.wjgnet.com
Williamson JS et al . CIMP status and rectal cancer therapy
histological examination of the resected specimen. The 
relationship between these molecular features, response 
to NACRT and oncological outcomes were analysed.
RESULTS
There were 160 patients analysed with a median follow-
up time of 46.4 mo. Twenty-one (13%) patients demon-
strated high levels of CIMP methylation (CIMP-H) and 
this was significantly associated with increased risk of 
extramural vascular invasion (EMVI) compared with 
CIMP-L [8/21 (38%) vs  15/99 (15%), P  = 0.028]. 
CIMP status was not related to tumour regression after 
radiotherapy or survival, however EMVI was significantly 
associated with adverse survival (P  < 0.001). Inter-
mediate CIMP status was significantly associated with 
KRAS mutation (P  = 0.01). There were 14 (9%) patients 
with a pathological complete response (pCR) compared 
to 116 (73%) patients having no or minimal regression 
after neoadjuvant chemoradiotherapy. Those patients 
with pCR had median survival of 106 mo compared to 
65.8 mo with minimal regression, although this was 
not statistically significant (P  = 0.26). Binary logistic 
regression analysis of the relationship between EMVI 
and other prognostic features revealed, EMVI positivity 
was associated with poor overall survival, advanced 
“T” stage and CIMP-H but not nodal status, age, sex, 
KRAS mutation status and presence of local or systemic 
recurrence.
CONCLUSION
We report a novel association of pre-treatment chara-
cterisation of CIMP-H with EMVI status which has 
prognostic implications and is not readily detectable on 
pre-treatment histological examination. 
Key words: Rectal cancer; CpG islands; Methylation
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: There is wide and unpredictable response 
of rectal cancer to neoadjuvant therapy which carries 
significant side effects and relies on limited pre-treat-
ment risk stratification. Methylation specific PCR was 
used to determine CpG island Methylator phenotype 
(CIMP) status in 160 rectal cancers and compared with 
response to therapy, clinical and pathological outcomes. 
CIMP status was not directly related to tumour regression 
but was related to extramural vascular invasion which 
confers an adverse survival risk.
Williamson JS, Jones HG, Williams N, Griffiths AP, Jenkins G, 
Beynon J, Harris DA. Extramural vascular invasion and response 
to neoadjuvant chemoradiotherapy in rectal cancer: Influence of 
the CpG island methylator phenotype. World J Gastrointest Oncol 
2017; 9(5): 209-217  Available from: URL: http://www.wjgnet.
com/1948-5204/full/v9/i5/209.htm  DOI: http://dx.doi.org/10.4251/
wjgo.v9.i5.209
INTRODUCTION
Locally advanced rectal cancer is usually treated with 
neoadjuvant chemoradiotherapy to downstage and/or 
downsize the tumour prior to surgery[1,2]. The response of 
rectal cancer to neoadjuvant therapy varies significantly 
between patients. The most successful outcome is a 
pathological complete response (pCR) in which no viable 
tumour cells are seen upon subsequent histological 
examination of the resected bowel. In this scenario 
patients have a significantly improved 5-year survival of 
up to 85%-100%, although any residual lymph-nodal 
involvement is associated with a significantly worse 
survival despite complete local tumour regression[3]. 
This compares favourably with those showing minimal 
response to radiotherapy who may expect 5-year survival 
of between 55%-66%[4].
pCR occurs in between 10%-20% of patients under-
going neoadjuvant chemoradiation therapy[4-6], however 
up to 30% of patients do not show any response[7]. 
Furthermore, those patients not responding to neo-
adjuvant treatment risk progression of their disease with 
either local progression or distant metastases during 
preoperative treatment. The use of imaging technology 
including magnetic resonance imaging (MRI) and endo-
rectal ultrasound are not sufficiently reliable[8,9] to be 
implemented as a sole means of discriminating between 
those with pCR and those without. 
The adverse prognostic value of extramural vascular 
invasion (EMVI) is well established and is known to be 
associated with poor survival[10], increased risk of local 
recurrence[11] and death[11-14]. Furthermore, the presence 
of EMVI has a relative risk of 3.7 for the development of 
systemic recurrence when detectable on preoperative MRI 
scanning[15]. The role of EMVI in directing treatment is 
relatively new and not well established. In particular, National 
Institute of Health and Care Excellence recommend that 
EMVI may confer a higher risk of recurrence in stage 
Ⅱ rectal cancers and suggest adjuvant chemotherapy 
may be considered in those patients with EMVI where 
the relative benefits of this treatment are not otherwise 
clear[16]. EMVI status may also influence the decision to 
offer neoadjuvant radiotherapy, as it has been demon-
strated that chemoradiation (CRT) can cause vessel 
fibrosis in EMVI-positive tumours, which may influence 
survival outcomes[17].
EMVI is detectable in rectal cancer patients on MRI, 
however, sensitivity and specificity are relatively low at 
62% and 88% respectively[17]. It is therefore important 
that not only is EMVI accurately characterised but 
should be available early to inform decisions regarding 
neoadjuvant chemoradiotherapy and influence overall 
treatment outcomes.
Developments in genetics and epigenetics lend 
support to the notion that tumours display characteristic 
clinicopathological and morphological features depending 
on the nature of specific combinations of molecular pat-
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terns[18]. In particular, the CpG island methylator phenotype 
(CIMP), which may account for up to 20% of all colorectal 
cancers[19,20], is associated with differences in tumour 
location, patient gender and association with characteristic 
gene mutations including KRAS, BRAF and p53[18], 
although this relationship has not been explored in EMVI. 
CpG islands are typically short (300-3000 base pairs) 
Cytosine-Guanine phosphodiester bonded sequences 
found in or around the promoter region of a gene where 
they are usually unmethylated if the genes are expressed. 
The CIMP phenotype is characterised by epigenetic 
DNA hyper-methylation and consequent suppression 
of key genes important in controlling cell growth and 
survival, which is associated with poor survival in rectal 
cancer[21,22]. It is becoming increasingly clear that 
epigenetic factors affecting specific gene promoter 
regions (CpG islands) can be equally as important as 
genetic alterations in all disease processes, as these can 
affect every component of gene regulation. Previous 
work has demonstrated that genetic factors such as 
KRAS mutation has an inverse relationship with EMVI[23] 
but little is known of the influence of epigenetic factors in 
the development of EMVI. The purpose of this study was 
to explore the relationship between CIMP and response 
to chemoradiotherapy and EMVI in rectal cancer.
MATERIALS AND METHODS
Patients undergoing neoadjuvant chemoradiotherapy and 
subsequent surgical resection for rectal adenocarcinoma 
with curative intent were identified from a prospectively 
maintained pathology database of all colorectal cancers 
between the years 2002 and 2011. All patients under-
went endoscopic diagnostic biopsy in order to confirm 
histological evidence of rectal adenocarcinoma prior to 
treatment. After pre-treatment staging with thoracic-
abdominal-pelvic computed tomography (CT), pelvic 
MRI, clinical examination under anaesthesia (EUA) and 
in some cases endorectal ultrasound (ERUS), patients 
were discussed by the multidisciplinary team and offered 
neoadjuvant chemoradiotherapy according to the local 
protocol. Local indications for neoadjuvant CRT were 
extensive mesorectal or pelvic sidewall nodal disease, 
predicted mesorectal fascia involvement by tumour 
and/or lymph nodes based on MRI imaging, or clinical 
fixity of tumour to surrounding structures. After a 6 to 
8 wk period following completion of chemoradiotherapy 
patients underwent restaging investigations (MRI, CT, 
ERUS and/or EUA) to assess response to treatment 
and to plan surgical resection. Standardised surgical 
techniques to maximise complete excision were used 
including total mesorectal excision and extralevator pelvic 
floor excision. In some cases multivisceral resection 
was required for tumours beyond conventional planes. 
Neoadjuvant radiotherapy in all cases was administered 
at South West Wales Oncology Centre (Singleton Hospital, 
Swansea, United Kingdom) and delivered with concurrent 
5-fluoroUracil (Capecitebine) according to local protocol. 
Pre-treatment biopsy specimens stained with Hae-
matoxylin and Eosin were examined by a consultant 
histopathologist to ensure they contained at least 
60% adenocarcinoma tissue. Post treatment resection 
specimens were examined by two consultant histo-
pathologists who were blinded to patient details and 
recorded their reports conforming to the Royal College of 
Pathologists colorectal cancer data set (2nd edition 2007) 
on separate sheets which were stored in a locked cabinet 
and not seen by other investigators until the data analysis 
stage. If the reports given by pathologists differed, a 
third pathologist would be asked to give an opinion 
and the final report reflected the consensus. When 
examining tumour regression scores, to ensure there 
was agreement between the two pathologists scoring 
the regression, Cohen’s kappa statistic was utilised to 
measure agreement between both raters. For the Royal 
College of Pathologists tumour regression score there 
was almost perfect agreement (k = 0.856 P < 0.001). 
Patients not completing a full course of neoadjuvant CRT 
or those not proceeding to surgery were excluded from 
this study. Patients with rectosigmoid junction tumours, 
history of inflammatory bowel disease or known high 
risk genetic predisposition to colorectal cancer (familial 
adenomatous polyposis or Lynch syndrome) and those 
undergoing treatment for recurrent cancer were also 
excluded. 
Demographic and clinical outcome data for patients in 
this study were gathered from patients’ case notes, clinic 
letters and computerised patient hospital records. Patients 
with local and systemic recurrence were also identified in 
this way. To identify patients who had died following their 
treatment, the NHS Wales Informatics Service (Myrddin) 
database was utilised which records the date of death for 
each patient if this has occurred. Overall survival, local 
and systemic recurrence free survival were calculated 
from the date of surgical resection until either the date 
of death or the date that recurrence was confirmed 
clinically, radiologically or histopathologically. If no death 
or recurrence had occurred, the reference date of last 
known follow-up was used to calculate survival. These data 
were also cross referenced against the Cancer Information 
Network System Cymru database which records data for 
all patients undergoing cancer treatment in South Wales 
to ensure its accuracy. Ethical approval for this study was 
granted by South West Wales REC (Project Ref No.:11/
WA/0256). Consent was not required in accordance with 
the Human Tissue Act 2004 (chapter 30).
DNA extraction
Formalin fixed paraffin embedded pre-treatment biopsy 
specimens were utilised for this study. Several represen-
tative 5 µm sections of the biopsy were cut and mounted 
unstained onto glass slides and DNA from these tissues 
was obtained using the MasterPure Complete DNA and 
RNA purification kit (Epicentre, Illumina, WI, United States).
The quantity and quality of DNA was measured at 
absorbance between 230 nm and 320 nm using spectro-
photometry (Nanodrop ND-1000, Software v3.1.2, 
Thermoscientific, DE, United States). DNA quantity was 
Williamson JS et al . CIMP status and rectal cancer therapy
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calculated by multiplying the measured concentration 
following spectrophotometry at 260 nm with the dilution 
factor. DNA was diluted to a working concentration of 
20 ng/µL. Purity was further analysed by calculating the 
absorbance at 260 nm to absorbance at 280 nm ratio.
Bisulfite conversion and methylation specific PCR
Methylation specific PCR is accomplished by performing 
bisulfite conversion of genomic DNA (Imprint DNA 
Modification Kit, Sigma Aldrich, United States). The PCR 
products were resolved using gel electrophoresis on a 
30% polyacrylamide gel. Depending on the methyla-
tion status of each CpG island, each patient could be 
classified as one of three epigenotypes; CIMP-High, 
Intermediate or Low using a two panel approach[24,25]. 
The first panel consists of SOCS1, MINT-1 and hMLH, 
which are associated strongly with CIMP-H. The second 
panel consist of NEUROG1, THBD, HAND1, ADAMTS1, 
IGFBP3. CIMP status could then be determined using 
the following system: (1) CIMP-High if ≥ 2/3 group 1 
markers methylated; (2) CIMP-Intermediate if < 2/3 
group 1 but ≥ 3/5 group 2 methylated; and (3) CIMP-
Low if < 2/3 group 1 and < 3/5 group 2 methylated.
KRAS and BRAF mutational analysis
Pyrosequencing analysis was performed in collaboration 
with the Leeds Cancer Research United Kingdom Centre, 
(Leeds Institute of Cancer Studies and Pathology, Clinical 
Sciences Building, level 6, St. James’s University Hospital, 
Leeds, LS9 7TF). Pyrosequencing conditions used were 
as previously published by this group[26]. Substitution and 
insertion/deletion mutations in KRAS codon 12, 13 and 
61 and BRAF-600 were examined for all specimens using 
this method.
Definitions
Tumours were defined as low (0-5 cm from anal verge), 
mid (5-10 cm) or high (10-15 cm) rectal based on pre-
operative rigid sigmoidoscopy and according to where 
the majority of the tumour was located. Predicted 
circumferential resection margin (CRM) involvement was 
defined by the presence of tumour foci (primary, nodal 
or extranodal deposit) within 1 mm of the mesorectal 
fascia or cylindrical resection margin for low tumours. 
An involved CRM was defined pathologically as tumour 
within 1 mm of the CRM. The original definition of EMVI 
describes “a rounded mass of tumour in an endothelium-
lined space either surrounded by a rim of smooth muscle 
or containing red blood cells[27]”. More recent definitions 
suggest venous invasion may also be suspected when 
a rounded or elongated tumour profile is identified 
adjacent to an artery, especially when no separate accom-
panying vein can be identified (the “orphan” artery 
sign), or where smooth tongues of tumour extend into 
pericolic/perirectal fat (“protruding tongue’’ sign)[28]. 
Statistical analysis
Statistical analysis was performed using SPSS v.18 
Chicago: SPSS Inc. Data was tested for normality using 
a Kolomogorov-Smirnov test, and a Student’s t-test 
was for analysis of normally distributed continuous 
data. Categorical variables were compared using χ 2 or 
Fishers exact test where expected frequencies were less 
than 10. Relationship between independent variables 
and time to event was compared using Kaplan-Meier 
methodology using the Log Rank test to determine 
significance. Multivariable analysis was performed using 
bivariate logistical regression and Cox Proportional 
Hazards modelling. Statistical significance was assumed 
at the 5% level. 
RESULTS
Patient and tumour characteristics
There were 160 patients included in this study. There 
were 113 (71%) males and 47 (29%) females and the 
average age by the time of surgery was 65.4 years. By 
the time of this analysis, 53 (33%) patients had died 
and the median time from surgery to death was 26.2 
mo (IQR 11.9-48.5).
Of the surviving patients, the median follow-up 
time from surgery was 46.4 mo (IQR 33.8-56.0). Local 
recurrence data were available for 152 patients and 
of these, 8 (5%) had evidence of local recurrence a 
median of 19.7 mo after surgery. Systemic recurrence 
data were available for 151 patients and of these, 37 
(25%) had evidence of systemic recurrence at median 
16.3 mo after surgery. Overall survival for all patients 
was estimated using Kaplan-Meier analysis at 73.3 mo 
(95%CI: 63.3-83.2). 4 (3%) patients had an involved 
CRM which was related to worse overall survival (74.1 
mo vs 37.2 mo, P = 0.047).
There were 14 (9%) patients with a pCR compared to 
116 (73%) patients having no or minimal regression after 
neoadjuvant chemoradiotherapy. Of those undergoing 
pCR, 8 were male, 6 were female and had a mean age 
of 66 years. None of the pCR patients demonstrated 
CIMP-H, whereas 2 were CIMP-I and 12 were CIMP-L. 
Those patients with pCR had median survival of 106 
mo compared to 65.8 mo with minimal regression, 
although this was not statistically significant (P = 0.26). 
There were 52 patients (33%) with demonstrable KRAS 
mutation, but only a single BRAF mutation was detected 
in the study sample. 
CIMP status analysis
CIMP status was determined in all patients, 21 (13%) 
were CIMP-H, 40 (25%) were CIMP-I and 99 (62%) were 
CIMP-L. Comparison of patient characteristics by CIMP 
status revealed no differences in mean age, gender, “T” 
or “N” stage, presence of systemic or local recurrence, 
CRM involvement, survival or tumour regression scores. 
Sub-analysis of individual CIMP markers with tumour 
regression scores revealed no significant differences. 
However, CIMP-H was significantly related to EMVI 
positivity with 8/21 (38%) CIMP-H patients demonstrating 
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EMVI compared with 15/99 (15%) who were CIMP-L. 
(CIMP-H/ EMVI+ 38% vs CIMP-L/EMVI+ 15%, Fishers 
exact, P = 0.028). Furthermore, a higher proportion of 
CIMP-I patients demonstrated KRAS mutation than other 
CIMP groups [CIMP-I + KRAS mutation 20/40 (50%) 
vs CIMP-H/L + KRAS mutation 32/120 (27%), Fishers 
exact, P = 0.01] (Table 1). 
None of 21 (0%) patients with CIMP-H tumours 
experienced a pCR compared with 12/99 (12%) CIMP 
L patients, however this was not statistically significant 
(Fishers exact = 0.12). There were 30 (19%) patients 
with EMVI-positivity on histopathological examination 
of the specimen. This was associated with a significant 
reduction in median overall survival (83.8 mo vs 43.9 
mo, P < 0.001, Figure 1). 
No patient with pCR displayed EMVI, whereas 29 
(25%) with RC Path score of 3 (minimal regression) 
displayed EMVI (P = 0.039, Table 2).
Multivariable analysis
Cox hazard regression analysis revealed that EMVI-
positivity was the only factor that was significantly related 
to adverse survival (Table 3).
Binary logistic regression analysis of the relationship 
between EMVI and other prognostic features revealed, 
EMVI positivity was associated with poor overall survival, 
advanced “T” stage and CIMP-H but not nodal status, 
age, sex, KRAS mutation status and presence of local or 
systemic recurrence (Table 4).
DISCUSSION
CIMP as a prognostic marker
CIMP-positivity has been implicated as an adverse survival 
predictor in patients with colorectal cancer[29-31], however, 
the majority of studies investigating survival outcomes 
in relation to methylation status regard colon and rectal 
cancers as one entity. Most investigators identify CIMP as 
an adverse prognostic feature, particularly in colorectal 
cancer taken as a whole and this was also corroborated 
by a recent meta-analysis including all colorectal sub sites, 
which found shorter survival in CIMP positive patients[32,33].
The current understanding of the role of CIMP in 
colorectal cancer is that tumours with a greater level of 
CpG island methylation (CIMP-High or CIMP +) have 
distinct molecular and clinical characteristics compared to 
low levels of CpG methylation (CIMP-Low or CIMP -)[34]. 
There is some evidence that CIMP-Positivity is related to 
shorter overall survival[35] and disease free survival[36], 
however the populations in these studies generally lack 
CIMP-H CIMP-I CIMP-L P  value
Mean age 66    69.2    63.9
Sex
Female   5 14 28
Male 16 26 71
ypT stage
0 or pCR   2   2 16
1   3   1   7
2   2 10 20
3 11 24 48
4   3   3   8
ypN stage
0 11 27 65
1   6   8 21
2   4   5 13
Systemic recurrence
Absent 14 30 66
Present   5   2 22
Local recurrence
Absent 20 37 87
Present   0   2   6
EMVI
Negative 13 33 84
Positive   8   7 15 CIMP-L vs CIMP-H 
p = 0.028
KRAS status
Wildtype 15 20 73
Mutant   6 20 26 KRAS Mut + CIMP-I 
p = 0.01
CRM 
Not involved 21 39 95
Involved   0   0   4
RC path score
1 (pCR)   0   2 12
2   6   9 14
3 15 29 73
Total 21 40 99
Table 1  Comparison of pathological features by CpG island 
methylator phenotype status
CRM: Circumferential resection margin; CIMP: CpG island methylator 
phenotype; EMVI: Extramural vascular invasion; pCR: Pathological 
complete response.
Survival functions
EMVI
Negative
Positive
Negative-censored
Positive-censored
Cu
m
 s
ur
vi
va
l
1.0
0.8
0.6
0.4
0.2
0.0
0.00   20.00    40.00    60.00   80.00   100.00  120.00
OS
No at risk (mo)     0 0-20 20-40 40-60 60-80 80-100 100-120
EMVI negative 130 114 77 23 8 3 1
EMVI positive   30   19   9   2 1 0 0
Figure 1  Overall survival by extramural vascular invasion positivity. Positive 
vs negative, p < 0.001. EMVI: Extramural vascular invasion; OS: Overall survival.
EMVI+ EMVI- P  value
RC Path 1 (pCR)   0 14 0.039
RC Path 2   1 28
RC Path 3 29 88
Table 2  Tumour regression scores (Royal College Patho-
logists data set) by extramural vascular invasion status
EMVI: Extramural vascular invasion; pCR: Pathological complete response.
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homogeneity of factors such as KRAS and BRAF mutation 
status, MSI status and tumour stage[34].
The present study did not demonstrate any re-
lationship between CIMP status and survival. CIMP 
status was however significantly associated with EMVI 
positivity which itself was associated with worse survival. 
Therefore it is likely that the relative contribution of 
these phenomena to prognosis is more complex than 
previously understood and should be studied in more 
detail and with particular distinction of rectal cancers 
from colon cancers.
Predicting response to chemoradiotherapy
Relatively few studies have studied the role of CIMP 
as a predictive marker of rectal cancer response to 
neoadjuvant chemoradiotherapy. A factor that com-
plicates the evidence is that there is no agreed definition 
on CIMP classification, and therefore widely ranging 
and contradicting results are found in the literature. Our 
research did not find that CIMP status was a predictor 
of response to chemoradiotherapy, although others 
have found that detecting the methylation status of 
individual gene promoter-regions affected the response 
to neoadjuvant treatment. 
Ebert et al[37] examined a total of 294 patients with 
colorectal cancer undergoing neoadjuvant chemotherapy 
(5-fluorouracil, oxaliplatin and irinotecan), and analysed 
the expression, methylation and function of the TFAP2E 
gene. They demonstrated that hypermethylation of the 
promoter regions of TFAP2E was associated with down-
regulation of the gene, and the subsequent up-regulation 
of a down-stream target. Furthermore, TFAP2E hyper-
methylation was a marker of 5-fluorouracil resistance in 
CRC in this study, but there was no effect on response to 
treatment with oxaliplatin or irinotecan.
CIMP and KRAS mutation
Ogino et al[38] examined methylation in 840 colorectal 
cancers led to the proposal that a further subset of 
intermediate methylation associated tumours exist but 
which do not fulfil the criteria for CIMP-High. These 
tumours (termed CIMP-intermediate) were independently 
associated with male gender and KRAS mutation. The 
three epigenotype model was further supported by 
Yagi et al[24], who used a large scale mass spectrometry 
analysis and hierarchical clustering to identify two panels 
of markers, the first to identify CIMP-High tumours 
and then a second panel to distinguish between CIMP-
intermediate and low tumours. In our research, CIMP-I 
had a significant association with KRAS-mutation 
compared to CIMP-H or CIMP-L tumours (P = 0.01), 
confirming this association in our patients, although no 
difference with regards to survival was demonstrated. 
CIMP classification and EMVI status
The adverse prognostic value of EMVI is well established 
Wald statistic OR 95%CI (lower) 95%CI (upper) P  value
T stage 1.735 1.392 0.851 2.279 0.188
N stage 0.268 0.857 0.479 1.535 0.605
EMVI 9.422 4.041 1.657 9.857 0.002
CIMP status 0.982 0.791 0.498 1.257 0.322
KRAS status 2.162 1.740 0.832 3.640 0.141
Sex 0.439 0.764 0.344 1.695 0.508
Local recurrence 0.861 1.763 0.532 5.839 0.353
Systemic recurrence 2.165 1.729 0.834 3.584 0.141
Tumour regression (pCR) 0.052 0.793 0.109 5.785 0.819
Involved CRM 0.146 1.339 0.299 6.002 0.703
Table 3  Multivariable analysis of pathological and molecular variables against overall survival
CRM: Circumferential resection margin; CIMP: CpG island methylator phenotype; EMVI: Extramural vascular invasion; pCR: Pathological complete 
response.
OR 95%CI (lower) 95%CI (upper) P  value
Overall survival 0.936 0.893   0.981 0.006
T stage 7.764 1.749 34.463 0.007
N stage 2.552 0.851   7.651 0.095
Age 1.024 0.969   1.081 0.405
Systemic recurrence 0.865 0.200   3.749 0.846
Sex 0.564 0.119   2.668 0.470
Local recurrence 1.841 0.193 17.562 0.596
Involved CRM 0.276 0.009   8.376 0.459
KRAS mutation 1.577 0.389   6.391 0.524
CIMP-H 6.368 1.091 37.162 0.040
Table 4  Binary logistic regression analysis; extramural vascular invasion positivity against overall survival and other pathological, 
demographic and molecular features
CRM: Circumferential resection margin; CIMP: CpG island methylator phenotype.
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and is known to be associated with poor survival[10] and 
has a relative risk of 3.7 for the development of sys-
temic recurrence when detectable on preoperative MRI 
scanning[15]. This is supported by data from the present 
study, which revealed significantly decreased survival 
with EMVI. 
EMVI was also associated with a lack of response 
to neoadjuvant chemoradiotherapy. If EMVI is present 
before treatment and is absent after treatment, then 
this would indicate a response, whereas failure of EMVI 
to regress would indicate a lack of response. However, 
the presence of EMVI is not currently detectable on 
histological analysis of pre-treatment biopsy specimens. 
In the present study, a novel association between EMVI 
and CIMP-H status was identified. This finding does 
provide a novel insight into potential mechanisms for the 
association of poor survival with CIMP-H seen in other 
studies. 
There are several mechanisms which may explain 
the link between CpG island hypermethylation and 
EMVI. For example, angiogenesis and subsequent local 
invasion of colorectal tumours has previously been linked 
to hypermethylation and silencing of micro-RNA-126 
(miRNA-126), which is associated with up-regulation 
of vascular endothelial growth factor and subsequent 
increased likelihood tumour invasion[39]. Other research 
has suggested that silencing the gene that codes for 
E-Cadherin (a molecule that forms the adherens junctions 
between normal cells, preventing spread of tumour cells 
across the epithelial basement membrane)[40] is associated 
with increased risk of EMVI and reduced response to 
neoadjuvant chemoradiotherapy and worse survival in 
rectal cancers[41]. Finally, the invasion of cancer cells into 
the surrounding extracellular matrix depends on the 
function of matrix metalloproteinases (MMPS), which 
are themselves regulated by tissue inhibitors of matrix 
metalloproteinases (TIMPS). In vitro and animal studies 
have demonstrated that aberrant epigenotypes affecting 
the MMP/TIMPS axis can lead to increased tumour invasion 
and migration in vitro and increased tumourigenesis and 
therapeutic reversal of this aberrant methylation can 
suppress these tumourigenic phenomenon[42,43].
Given that CIMP is deemed to represent a phenotypic 
hypermethylated state, it is likely that the presence of the 
CIMP-H state explains the association of EMVI-positivity 
and poor survival seen in rectal cancer patients. The 
detection of a hypermethylated state in individual gene 
promoter regions may well further our understanding of 
the response to chemoradiotherapy in the future.
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COMMENTS
Background
There is wide variation in response to neoadjuvant chemoradiotherapy (NACRT) 
in rectal cancer, which has a significant impact on survival. There is currently 
no reliable means to predict response to NACRT, which carries significant 
side effects. The CpG island methylator phenotype (CIMP) is characterised by 
epigenetic DNA hyper-methylation and suppression of key genes controlling 
cell growth and survival and occurs in approximately 20% of colorectal cancers. 
The role of CIMP status in the prognosis and response of rectal cancer to 
neoadjuvant therapy is not well understood but evidence is emerging that it may 
be an adverse prognostic indicator. 
Research frontiers
Previous studies have demonstrated an association of high levels of CIMP 
associated methylation with adverse survival and differential responses to 
neoadjuvant treatment where methylation is seen in specific genes in rectal 
cancer, however, the mechanism and exact nature of this association is not 
clear.
Innovations and breakthroughs
This study reports a novel association of CIMP related methylation with extra 
mural vascular invasion which represents an adverse prognostic indicator and 
provides a novel insight into potential mechanisms for the association of poor 
survival with CIMP H which may be related to epigenetic silencing of the normal 
inhibitory mechanisms which prevent cell migration, proliferation and vascular 
invasion.
Applications
Extramural vascular invasion (EMVI) has recently been associated with adverse 
survival and risk of metastasis and although it features in the National Institute 
of Health and Care Excellence United Kingdom guidelines for the treatment 
of rectal cancer, suggesting that short course neoadjuvant therapy should 
be considered in these patients on this basis, the current guidelines concede 
that the risks and benefits in this group are unclear and further research is 
needed. Indeed the prediction of EMVI on preoperative imaging is notoriously 
difficult and non-reproducible. EMVI is detectable in rectal cancer patients on 
magnetic resonance imaging, however, sensitivity and specificity are relatively 
low at 62% and 88% respectively and it is possible that in future, CIMP status 
could be used to enhance preoperative EMVI detection and subsequent risk 
stratification.
Terminology
CpG islands are typically short (300-3000 base pairs) Cytosine-Guanine 
phosphodiester bonded sequences found in or around the promoter region of 
a gene where they are usually unmethylated if the genes are expressed. The 
CIMP phenotype is characterised by epigenetic DNA hyper-methylation and 
consequent suppression of key genes important in controlling cell growth and 
survival. High levels of CIMP associated methylation (deemed CIMP-High), 
are associated with poor survival in rectal cancer. Extramural vascular invasion 
of a tumour is defined as “a rounded mass of tumour in an endothelium-lined 
space either surrounded by a rim of smooth muscle or containing red blood 
cells”. Venous invasion may also be suspected when a rounded or elongated 
tumour profile is identified adjacent to an artery, especially when no separate 
accompanying vein can be identified or where smooth tongues of tumour 
extend into pericolic/perirectal fat.
Peer-review
The authors aimed to identify whether CIMP status is predictive of response 
to neoadjuvant chemoradiotherapy and outcomes in rectal cancer. They found 
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that a novel association of CIMP status with extramural vascular invasion which 
represents an adverse prognostic indicator and provides a novel insight into 
potential mechanisms for the association of poor survival with CIMP-H rectal 
cancers. The study is well-designed and presented. The results are all clear 
and understandable, the descriptions of methods and materials are also clear.
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